Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO… Ended

2023-504594-20-00 Healthy volunteers 2025-01-06
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with… Ended

2024-511616-24-00 Relapsed and/or Refractory B-cell Lymphoma 2024-12-06
Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors. Ended

2024-513281-19-00 Nasopharyngeal Carcinoma 2024-11-25
Phase I trial of the new drug PhOx430 (inhibitor of the enzyme glucosaminyltransferase V) in patients with advanced solid tumors; first test… Ended

2024-516574-30-00 Adult patients with advanced or metastatic solid malign 2024-10-15
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastat… Ended

2023-509867-26-00 Advanced/metastatic solid tumor 2024-10-14
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination wit… Ended

2023-507377-17-00 Advanced Melanoma 2024-08-28
Safety and preliminary efficacy of BNT314 in cancer patients with malignant solid tumors Ended

2023-506053-38-00 Advanced or metastatic malignant solid tumors 2024-08-27
Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis. Ended

2023-510456-23-00 Idiopathic Pulmonary Fibrosis 2024-08-14
A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours Ended

2023-508764-30-00 Locally advanced or metastatic solid tumors 2024-07-31
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL Ended

2023-509258-71-00 relapsed or refractory B‑cell non-Hodgkin lymphomas 2024-07-24
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell… Ended

2023-503594-38-00 Select B-Cell malignancies. 2024-07-15
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of… Ended

2023-507363-20-00 Amyotrophic lateral sclerosis (ALS) 2024-07-12
Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Ended

2023-509047-26-00 Dose Escalation: Non-small cell lung cancer (NSCLC), co 2024-06-13
A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar… Ended

2023-508459-37-00 HER2-positive advanced solid tumours 2024-05-28
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended

2023-509555-13-00 Relapsing multiple sclerosis 2024-05-15
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalim… Ended

2023-504598-18-00 Advanced solid tumors 2024-04-03
IAVI C110 HIV Vaccine Trial Ended

2023-508157-15-01 Human Immunodeficiency Virus (HIV) 2024-03-19
A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced… Ended

2022-502381-25-01 Thymic Carcinoma 2024-03-15
First-in-human safety study of pancreatic islet transplantation without immune suppression in adult subjects with type 1 diabetes Ended

2023-507988-19-00 Diabetes type I 2024-03-08
A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose wh… Ended

2023-505594-32-00 Advanced solid tumors 2024-02-20
A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy… Ended

2023-506393-12-00 Advanced non-small cell lung cancer 2024-02-13
Study of HRO761 alone or in combination in cancer patients with specific DNA alterations called Microsatellite Instability-High or Mismatch … Ended

2022-502314-93-00 MSIhi or dMMR advanced unresectable or metastatic solid 2024-02-05
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects wit… Ended

2022-500849-24-00 Advanced Solid Tumors 2023-11-07
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product K… Ended

2023-503909-11-01 Ovarian cancer 2023-10-30